Oncolys BioPharma

4588.TTSE GROWTHPharmaceutical

Key numbers · FY ended 2025-12

Revenue¥29m-9.0% YoY Operating income−¥2.0bn—Total assets¥4.6bn+42.4% YoY EPS (basic)¥-80-3.7% YoY

Full financial history and reports →

Stock price4588 · View chart ↗

Open the price chart on TradingView.

Latest filings

Wed, May 20 · JST1 filing

13:215% STAKEOncolys BioPharma · Gomi Daisuke · 5.04% → 3.91%−1.13pp

Fri, Jan 16 · JST1 filing

15:205% STAKEOncolys BioPharma · Gomi Daisuke · 5.04%new 5.04%

Fri, Nov 21 · JST1 filing

13:595% STAKEOncolys BioPharma · SMBC Nikko Securities Inc. · 9.08% → 4.58%−4.50pp

Mon, Oct 27 · JST1 filing

13:085% STAKEOncolys BioPharma · SMBC Nikko Securities Inc. + 1 joint holder · 10.17% → 9.08%−1.09pp

Tue, Aug 12 · JST1 filing

12:285% STAKEOncolys BioPharma · SMBC Nikko Securities Inc. · 14.79%new 14.79%

All filings →

Major holders (5%+) · 0

Holder	Stake	Change	Filed

No holder currently reports 5% or more.

Each holder's own ratio from its most recent large-shareholding report.